期刊
PHARMACOGENOMICS JOURNAL
卷 12, 期 2, 页码 156-164出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2010.65
关键词
antipsychotic-induced weight gain; schizophrenia; pharmacogenetics; dopamine receptor genes; polymorphisms; haplotypes
资金
- Abbott Labs
- ACADIA
- Bristol-Myers Squibb
- Eli Lilly
- Jansse
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Memory
- Cephalon
- Minster
- Aryx
- BiolineRx
- Allon
- Bioline
- Forest Labs
- Janssen
- Merck
- Novartis
- Solvay
- Wyeth
- CIHR [MOP-15007, MOP-89853]
- NARSAD
- Prentiss Foundation
- Ritter Foundation
- Hintz family
- Peterson Family
- Bebensee fellowship
- [MH41468]
Antipsychotic-induced weight gain has emerged as a serious complication in the treatment of patients with most antipsychotics. We have conducted the first in-depth examination of dopamine receptor genes in antipsychotic-induced weight gain. A total of 206 patients (139 of European descent and 56 African Americans) who underwent treatment for chronic schizophrenia or schizoaffective disorder were evaluated after on average over 6 weeks of treatment. Thirty-six tag single nucleotide polymorphisms (SNPs) and one variable-number tandem repeat, spanning the five dopamine receptor genes (DRD1-DRD5) were analyzed. In the total sample, we found a nominally significant association between the DRD2 rs1079598 marker and weight change using a cutoff of 7% gain (P = 0.03). When stratifying the sample according to ethnicity and antipsychotics with highest risk for weight gain, we found significant associations in three DRD2 SNPs: rs6277 (C957T), rs1079598 and rs1800497 (TaqIA). The other genes were primarily negative. We provide evidence that dopamine receptor DRD2 gene variants might be associated with antipsychotic-induced weight gain in chronic schizophrenia patients. The Pharmacogenomics Journal (2012) 12, 156-164; doi:10.1038/tpj.2010.65; published online 17 August 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据